<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992949</url>
  </required_header>
  <id_info>
    <org_study_id>CPX-351 TA-SMP</org_study_id>
    <nct_id>NCT04992949</nct_id>
  </id_info>
  <brief_title>Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm</brief_title>
  <acronym>CPX-351 TA-SMP</acronym>
  <official_title>A Phase II Study of CPX-351 Monotherapy in Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acute Leukemia French Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French Intergroup of Myeloproliferative syndromes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The three classic myeloproliferative neoplasms (MPNs) include polycythemia Vera (PV),&#xD;
      essential thrombocythemia (ET) and primary myelofibrosis (PMF). The natural history of these&#xD;
      MPNs is the possible progression to acute myeloid leukemia (MPN-blast phase) at variable&#xD;
      percentage depending the entity. Leukemic transformation of MPN occurs in 8% to 23% of&#xD;
      primary myelofibrosis (PMF) patients in the first 10 years after diagnosis and in 4% to 8% of&#xD;
      polycythemia vera (PV) and essential thrombocytosis (ET) patients within 18 years after&#xD;
      diagnosis. The risk for leukemic transformation is increased by exposure to cytotoxic&#xD;
      chemotherapy. The molecular pathogenesis of MPN-blast phase remains an area of active&#xD;
      research.&#xD;
&#xD;
      The prognosis of blast phase MPNs is very poor : approximately 50% of the patients are deemed&#xD;
      eligible for intensive treatment (ie. conventional induction chemotherapy regimen with&#xD;
      anthracyclines and cytarabine). The patients who are not fit for such intensive treatment&#xD;
      approach due to age or comorbidities, are treated with Hypomethylating agents, low dose&#xD;
      palliative chemotherapy, or supportive care. Nevertheless, there is a need for more effective&#xD;
      and better tolerated treatment approaches in order to increase the response rate and hence,&#xD;
      the transplant rates which should translate into improved survival.&#xD;
&#xD;
      CPX-351 is a new formulation of cytarabine and daunorubicin encapsulated at a fixed 5:1&#xD;
      molar-ratio in liposomes that exploits molar ratio-dependent drug-drug synergy to enhance&#xD;
      antileukemic efficacy.&#xD;
&#xD;
      Based on similarities between post-myelodysplastic syndrome (MDS) and post-MPN secondary AML&#xD;
      in terms of disease resistance to chemotherapy, of fragile patient profile, The hypotheses&#xD;
      made is that CPX-351 may improve the results of induction chemotherapy without increasing its&#xD;
      toxicity and therefore may increase the proportion of patients who could benefit from an&#xD;
      allogeneic Stem Cell Transplantation (SCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the Complete Remission (CR/CRi) rate after&#xD;
      treatment with CPX-351 in patients with AML secondary to myeloproliferative neoplasms&#xD;
      (post-MPN AML).&#xD;
&#xD;
      The hypotheses made is that treatment with CPX-351 will improve the historical response rate&#xD;
      from 45% to 65%. The exact single stage Phase II design was used to calculate the number of&#xD;
      patients. The null hypothesis H0 is that the probability p of CR/CRi rate with CPX351 is&#xD;
      equal or lower than the historical rate p0 of 45% (H0: p≤p0). The alternative hypothesis H1&#xD;
      that is p&gt;p0, supposing that CR/CRi rate will be 65% using CPX351. Considering an alpha risk&#xD;
      of 5% and a power of 80%, 42 patients will be included, and H0 will be rejected if at least&#xD;
      25 patients achieve CR /CRi (R-project, &quot;clinfun&quot; package).&#xD;
&#xD;
      Inclusion period : 36 months&#xD;
&#xD;
      Treatment period (6 months) :&#xD;
&#xD;
        -  one or two cycles of induction treatment with CPX-351 (depending on CR/CRi achieving).&#xD;
           If CR/CRi is not achieved following the induction phase, patients will go off study.&#xD;
&#xD;
        -  2 courses of consolidation therapy with CPX-351 (patients for whom an allo-SCT is&#xD;
           planned will receive a maximum of one consolidation cycle)&#xD;
&#xD;
      All included patients will be followed for 60 days after the End of Treatment (EOT) or at the&#xD;
      date of allogeneic stem cell transplantation when appropriate : the day-60 follow-up visit&#xD;
      will be the End Of Study (EOS) visit. The anti-leukemic chemotherapy administrated after&#xD;
      relapse will be recorded.&#xD;
&#xD;
      After completion of the study, subjects will be followed-up at regular intervals (every 3&#xD;
      months) to collect information on the subjects' survival and disease (relapse) status.&#xD;
      Survival status will be collected until death, or withdrawal of consent or lost to follow-up,&#xD;
      whichever occurs first..&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label multicenter phase II non-randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of CR/CRi after first induction therapy</measure>
    <time_frame>After 28 to 42 days after one cycle of 5 days of CPX351</time_frame>
    <description>Rate of CR/CRi according to ELN2017 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of CR/CRi after second induction therapy</measure>
    <time_frame>If applicable, after 28 to 31 days after a second cycle of 3 days of CPX351</time_frame>
    <description>Rate of CR/CRi according to ELN2017 criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myeloproliferative Syndrome</condition>
  <arm_group>
    <arm_group_label>CPX351</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of CONSOLIDATION therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Induction : patients will receive induction treatment with CPX-351 100 U/m2 on days 1, 3, and 5. Patients who fail to achieve CR/CRi after the induction cycle will be offered a second induction course of CPX-351 100 U/m2 on days 1 and 3, at the investigators' discretion. If CR/CRi is not achieved following the second induction cycle, patients will go off study&#xD;
Consolidation : patients in CR/CRi after induction cycle will receive up to 2 course of consolidation therapy with CPX-351 65 U/m2 on days 1 and 3. CPX351 doses could be reduced to 65 U/m2 on day 1 in case of unacceptable toxicity following the previous course.&#xD;
Allo-SCT : patients for whom an allo-SCT is planned will receive a maximum of one consolidation cycle</description>
    <arm_group_label>CPX351</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of newly secondary AML according to WHO 2016 classification following an&#xD;
             antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET),&#xD;
             Polycythemia Vera (PV), primary or secondary Myelofibrosis&#xD;
&#xD;
          -  Performance status 2 Eastern Cooperative Oncology Group (ECOG) grading.&#xD;
&#xD;
          -  Eligible for standard intensive chemotherapy&#xD;
&#xD;
          -  Absence of concomitant severe cardiovascular disease which would make intensive&#xD;
             chemotherapy impossible, i.e. arrhythmias requiring chronic treatment, congestive&#xD;
             heart failure or symptomatic ischemic heart disease, reduced left ventricular function&#xD;
             assessed by multigated acquisition (MUGA) scan or echocardiogram. Cardiac ejection&#xD;
             fraction ≥ 50% by echocardiography ou MUGA&#xD;
&#xD;
          -  Patient must have adequate organ function as indicated by the following laboratory&#xD;
             values:&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                    -  Serum creatinine: &lt; 2 mg/dl OR calculated creatinine clearance*: ≥ 30 mL/min&#xD;
                       by MDRD formula for patients with creatinine levels &gt; 1.5 X institutional&#xD;
                       Upper Limit Normal (ULN)&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Serum total bilirubin: ≤ 2.5 X ULN OR direct bilirubin ≤ ULN for patients&#xD;
                       with total bilirubin levels ≥ 2 mg/dL unless Gilbert's Syndrome&#xD;
&#xD;
                    -  Aspartate-Amino-Transferase (ASAT) and Alanine-Transaminase (ALAT): ≤ 2.5&#xD;
                       times ULN&#xD;
&#xD;
                    -  Alkaline Phosphatase: ≤ 5 X ULN, if &gt; 2.5 X ULN, then liver fraction should&#xD;
                       be ≤ 2.5 X ULN *Creatinine clearance should be calculated per institutional&#xD;
                       standard&#xD;
&#xD;
          -  Life expectancy should be of 12 weeks at least according to investigator evaluation&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             (β-hCG) within 72 hours prior to receiving the first dose of CPX-351. Female patients&#xD;
             who are not post-menopausal, free from menses for &gt; 2 years or surgically sterilized,&#xD;
             will have to use adequate barrier methods of contraception to prevent pregnancy or&#xD;
             agree to abstain from becoming pregnant throughout the study, starting with Visit 1.&#xD;
&#xD;
          -  Male patients agree to use an adequate method of contraception for the duration of the&#xD;
             study. Men should be advised not to father a child while receiving CPX-351 and for 3&#xD;
             months post study.&#xD;
&#xD;
          -  Patients have the ability to understand and willingness to sign an informed consent&#xD;
             form indicating the investigational nature of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MPN/MDS mixed types&#xD;
&#xD;
          -  Prior therapy for AML transformation except for Hydroxyurea&#xD;
&#xD;
          -  Prior treatment with growth factors such as erythropoietin alfa (EPO) or granulocyte&#xD;
             colony-stimulating factor (G-CSF), low-dose oral chemotherapy or Hypomethylating&#xD;
             agents chemotherapy given in the chronic phase of MPN in the 30 days before inclusion,&#xD;
             except for hydroxyurea.&#xD;
&#xD;
          -  Uncontrolled undercurrent illness or circumstances that could limit compliance with&#xD;
             the study, including but not limited to the following: symptomatic congestive heart&#xD;
             failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or&#xD;
             psychiatric or social conditions that may interfere with patient compliance.&#xD;
&#xD;
          -  Active and uncontrolled infection&#xD;
&#xD;
          -  Current participation or participation in a study with an investigational compound or&#xD;
             device within 30 days of initial dosing with study drug&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or HIV-related malignancy&#xD;
&#xD;
          -  Clinically active hepatitis B or hepatitis C infection.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of CPX-351.&#xD;
&#xD;
          -  Currently active second malignancy, other than non-melanoma skin cancer and in situ&#xD;
             carcinoma of the cervix. Patients are not considered to have a &quot;currently active&quot;&#xD;
             malignancy if they have completed therapy for a prior malignancy, are disease free&#xD;
             from prior malignancies for &gt;3 years or are considered by their physician to be at&#xD;
             less than 30% risk of relapse&#xD;
&#xD;
          -  Clinical evidence of Central Nervous System Leukemia.&#xD;
&#xD;
          -  Pregnancy or breastfeeding during the projected duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme REY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie ROLLAND-NEYRET</last_name>
    <phone>(0)4 76 76 50 96</phone>
    <phone_ext>+33</phone_ext>
    <email>VRolland-neyret@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AMIENS - CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Delphine LEBON, MD</last_name>
      <email>lebon.delphine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ANGERS - CHU - Maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathilde HUNAULT, Dr</last_name>
      <phone>02 41 35 45 82</phone>
      <email>mahunault@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AVIGNON - Centre Hospitalier</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Safia CHEBREK, Dr</last_name>
      <phone>+33 4 32 75 93 00</phone>
      <email>chebrek.safia@ch-avignon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BAYONNE - CH de la Côte Basque - Hématologie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Baptiste ROBIN, Dr</last_name>
      <email>jbrobin@ch-cotebasque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AVICENNE - Centre de Recherche Clinique</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thorsten BRAUN, Pr</last_name>
      <email>thorsten.braun@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BREST - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gaëlle GUILLERM, MD</last_name>
      <email>gaelle.guillerm@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAEN - CHU Caen - IHBN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain CHANTEPIE, Dr</last_name>
      <email>chantepie-s@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLAMART - Hôpital d'Instruction des Armées de Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre ARNAUTOU, MD</last_name>
      <email>parnautou@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand - Chu Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Romain Guieze, MD</last_name>
      <phone>+33473750766</phone>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRETEIL - CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile PAUTAS, MD</last_name>
      <email>cecile.pautas@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grenoble - CHUGA - Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu MEUNIER, Dr</last_name>
      <email>Mmeunier2@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille Chu</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno QUESNEL</last_name>
      <email>bruno.quesnel@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Limoges - Chu</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amélie PENOT</last_name>
      <email>amelie.penot@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LYON-Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Amine BELHABRI, MD</last_name>
      <email>amine.belhabri@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MARSEILLE - Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme REY, Dr</last_name>
      <email>reyj@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MONTPELLIER - Hôpital Saint-Eloi - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eve GEHLKOPF, Dr</last_name>
      <email>e-gehlkopf@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NANTES - Hôpital Hôtel Dieu - Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre PETERLIN, Dr</last_name>
      <phone>+33(0)2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NICE - Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauris GASTAUD, MD</last_name>
      <email>lauris.gastaud@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NICE - CHU - Hopital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas CLUZEAU</last_name>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NIMES - CHU Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric JOURDAN, Dr</last_name>
      <phone>04 66 68 32 31</phone>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ORLEANS - CHR - Hématologie</name>
      <address>
        <city>Orléans</city>
        <zip>44100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Magda ALEXIS, Dr</last_name>
      <email>magda.alexis@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris St Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ollivier LEGRAND, Pr</last_name>
      <email>ollivier.legrand@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis DREVON, Pr</last_name>
      <email>louis.drevon@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BORDEAUX - Hôpital Haut-Levêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Arnaud PIGNEUX, Pr</last_name>
      <email>arnaud.pigneux@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LYON Sud - Centre Hospitalier</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69036</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maël HEIBLIG, MD</last_name>
      <email>mael.heiblig@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>POITIERS - Hôpital La Milétrie - Hématologie Clinique</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria-Pilar GALLEGO-HERNANZ, Dr</last_name>
      <phone>+33(0)5 49 44 44 44</phone>
      <email>maria-pilar.gallego-hernanz@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>REIMS - Hôpital Robert Debré - Hématologie Clinique</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Chantal HIMBERLIN, Dr</last_name>
      <phone>+33(0)3 26 78 36 44</phone>
      <email>chimberlin@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RENNES - Hôpital Pontchaillou - Hématologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc BERNARD, Dr</last_name>
      <phone>+33(0)2 99 28 99 86</phone>
      <email>marc.bernard@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Strasbourg - Icans</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie Pierre LEDOUX, MD</last_name>
      <email>mp.ledoux@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulouse - IUCT Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian RECHER, Pr</last_name>
      <phone>+33 5 31 15 63 55</phone>
      <email>recher.christian@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>TOURS - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alban VILLATE, MD</last_name>
      <email>a.villate@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NANCY - CHU de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline BONMATI, Dr</last_name>
      <email>c.bonmati@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VERSAILLES - Hôpital André Mignot</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Laure TAKSIN-BRESSOT, Dr</last_name>
      <email>altaksin@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Florence PASQUIER, MD</last_name>
      <email>florence.pasquier@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Courtier F, Carbuccia N, Garnier S, Guille A, Adélaïde J, Cervera N, Gelsi-Boyer V, Mozziconacci MJ, Rey J, Vey N, Chaffanet M, Birnbaum D, Murati A. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases. Haematologica. 2017 Jan;102(1):e11-e14. doi: 10.3324/haematol.2016.152363. Epub 2016 Oct 14.</citation>
    <PMID>27742771</PMID>
  </reference>
  <reference>
    <citation>Luque Paz D, Jouanneau-Courville R, Riou J, et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887-4897. Blood Adv. 2020 Nov 24;4(22):5651. doi: 10.1182/bloodadvances.2020003711.</citation>
    <PMID>33206963</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

